GlassScriptPhysician profile
Timothy C Williams
NPI 1538246103
$4,050.53
in general payments reported to CMS, 2019-2025
40 companies · $84.47 in 2025
The $84.47 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $796 · 2020: $480 · 2021: $1,388 · 2022: $1,029 · 2023: $184 · 2024: $89.39 · 2025: $84.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $357.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $972.22 | 2019-2024 | Wegovy |
| Lilly USA, LLC | $367.19 | 2019-2022 | |
| Abbvie INC. | $262.03 | 2019-2023 | Ubrelvy |
| Abbott Laboratories | $238.94 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $188.02 | 2019-2022 | |
| Amgen INC. | $167.48 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $160.16 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $159.57 | 2019-2022 | |
| Amarin Pharma, INC. | $118.76 | 2019-2022 | |
| Antares Pharma, INC. | $114.35 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $113.98 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.84 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $100.00 | 2021 | |
| Corcept Therapeutics | $90.28 | 2021-2022 | |
| Mannkind Corporation | $80.66 | 2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.